← All trials
NCT05274984
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2022
- Primary completion
- Mar 3, 2022
- Completion date
- Apr 3, 2022
- First posted
- Mar 11, 2022
- Last posted
- Mar 11, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Iuliu Hatieganu University of Medicine and PharmacyLead sponsor
- Iuliu Hatieganu University of Medicine and PharmacyReponsible party - principal investigator
- Iuliu Hatieganu University of Medicine and PharmacyStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.